ReviewBrain pathology (Zurich, Switzerland)2006
Neurotrophins and peripheral neuropathies.
Review in Brain pathology (Zurich, Switzerland), 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 17 citations in OpenAlex.
- AAVrh74.tMCK.NT-3 Surrogate Gene Therapy in a Mouse Model of CMT2A.International journal of molecular sciences · 2026Article
- AAV1.NT3 gene therapy mitigates the severity of autoimmune encephalomyelitis in the mouse model for multiple sclerosis.Gene therapy · 2025Article
- AAV1.tMCK.NT-3 gene therapy improves phenotype inBrain communications · 2024Article
- Elongator promotes neuritogenesisFrontiers in cell and developmental biology · 2022Article
- Gene therapy to promote regeneration in Charcot-Marie-Tooth disease.Brain research · 2020Review
- New Therapeutics Options for Pediatric Neuromuscular Disorders.Frontiers in pediatrics · 2020Review
- AAV1.NT-3 gene therapy attenuates spontaneous autoimmune peripheral polyneuropathy.Gene therapy · 2016Article
- AAV1.NT-3 gene therapy for charcot-marie-tooth neuropathy.Molecular therapy : the journal of the American Society of Gene Therapy · 2014Article
- Review
- Neural and molecular features on Charcot-Marie-Tooth disease plasticity and therapy.Neural plasticity · 2012Review
- Neurotrophic factors in neurodegeneration.Brain pathology (Zurich, Switzerland) · 2006Review
- Pathophysiological mechanisms for actions of the neurotrophins.Brain pathology (Zurich, Switzerland) · 2006Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peripheral neuropathy is a common disorder seen in general neurology and neuromuscular specialty clinics. Treatment options directed at the underlying cause can only be offered in a handful of conditions, such as those with possible autoimmune etiology. The remainder fall into the idiopathic or genetic category with no known treatment. This review surveys the evidence supporting the rationale for the therapeutic use of neurotrophins and other neurotrophic factors in these disorders in relationship to the underlying pathobiological process. Previous clinical trials are assessed, and increasingly better understood and appreciated therapeutic potential of neurotrophins is emphasized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.